Anti-EIF5A2 Magnetic Beads-IP Kit Product Components
| Components | Storage |
| Anti-EIF5A2 Magnetic Beads1,3 | 2-8℃ for 12 months |
| NP40 Cell Lysis Buffer2 | -20℃ for 12 months |
| 5×TBST（pH7.4） | |
| 1×TBST（pH7.4） | |
| ddH2O | |
| CD166 Positive Cell Lysate | -20℃ for 12 months |
| Alkaline Elution Buffer | 2-8℃ for 12 months |
| Acidity Elution Buffer | 2-8℃ for 12 months |
| Neutralization Buffer | 2-8℃ for 12 months |
[1] The IP KIT contains anti-EIF5A2 magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).
[2] Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.
[3] Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.
Anti-EIF5A2 Magnetic Beads-IP Kit Product Description
The Anti-EIF5A2 magnetic Beads, conjugated with Anti-EIF5A2 antibody, are used for immuneprecipitation (IP) of EIF5A2 proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing EIF5A2 proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound EIF5A2 proteins are dissociated from the magnetic beads using an elution buffer. Anti-EIF5A2 Magnetic Beads-IP Kit Antibody Information
Immunogen
Recombinant Human EIF5A2 protein (Catalog#14927-H07E)
Species Reactivity
Human EIF5A2
Source
Polyclonal Human Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Human EIF5A2 (rh EIF5A2; Catalog#14927-H07E; Q9GZV4; Met1-Lys153). EIF5A2 specific IgG was purified by Human EIF5A2 affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification
Anti-EIF5A2 Magnetic Beads Immunoprecipitation (IP) Kit Alternative Names
Anti-EIF-5A2ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-eIF5AIIALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit
EIF5A2 Background Information
Eukaryotic translation initiation factor 5A2 (EIF5A2) has been demonstrated to be upregulated in numerous types of human cancer and is associated with cancer progression. Silencing of EIF5A2 in the NSCLC cells resulted in the downregulation of the tumorigenic proteins, apoptosis regulator Bcl-2 and myc proto-oncogene protein, and upregulation of E-cadherin, suggesting that EIF5A2 promotes proliferation and metastasis through these proteins. EIF5A2 may therefore serve as a novel therapeutic target for the treatment of NSCLC. EIF5A2 might be a novel therapeutic target for the inhibition of NPC progress. EIF5A2 overexpression may contribute to cancer progression and poor prognosis, it could be a novel potential prognostic marker for FIGO stage I-II cervical cancer. EIF5A2 upregulation plays an important oncogenic role in gastric cancer. EIF5A2 may represent a new predictor for poor survival and is a potential therapeutic target for gastric cancer. The eukaryotic initiation factor 5A2 (EIF5A2) over-expression enhances HCC cell metastasis. EIF5A2, as a target of PI3K/Akt, promotes melanoma cell invasion and may serve as a promising prognostic marker and a potential therapeutic target for melanoma.
Full Name
eukaryotic translation initiation factor 5A2
新浪微博
腾讯微博
QQ空间
客服
